Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4303393 | 1.00 | OPRD1 (0.39) | OPRD1OPRK1OPRM1OPRL1CYP2D6 | |
| SCHEMBL15358903 | 1.00 | OPRD1 (0.39) | OPRD1OPRK1OPRM1OPRL1CYP2D6 | |
| SCHEMBL4294409 | 1.00 | OPRD1 (0.39) | OPRD1OPRK1OPRM1OPRL1CYP2D6 | |
| SCHEMBL25429324 | 1.00 | OPRD1 (0.39) | OPRD1OPRK1OPRM1OPRL1CYP2D6 | |
| SCHEMBL7003092 | 1.00 | OPRD1 (0.39) | OPRD1OPRK1OPRM1OPRL1CYP2D6 | |
| SCHEMBL25429321 | 1.00 | OPRD1 (0.39) | OPRD1OPRK1OPRM1OPRL1CYP2D6 | |
| SCHEMBL5837912 | 0.89 | OPRD1 (0.42) | OPRD1OPRK1OPRM1OPRL1CYP2D6 | |
| SCHEMBL5837913 | 0.89 | OPRD1 (0.42) | OPRD1OPRK1OPRM1OPRL1CYP2D6 | |
| SCHEMBL25844736 | 0.88 | OPRD1 (0.39) | OPRD1OPRK1OPRM1OPRL1CYP2D6 | |
| SCHEMBL25428365 | 0.85 | OPRD1 (0.37) | OPRD1OPRK1OPRM1OPRL1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115624-B1 | Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48 | NOVO NORDISK A/S (DK) | 2006-10-03 | — | — | US | disclosed |
| EP-1214324-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK AS (DK) | 2006-06-14 | — | — | EP | disclosed |
| EP-1301516-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK AS (DK) | 2006-03-22 | — | — | EP | disclosed |
| US-6613903-B2 | Such as 7-(benzoylamino-methyl)-2-(oxalyl-amino)-4,5,6,7-tetrahydro-thieno(2,3 -c)pyridine-3-carboxylic acid for treatment of diabetes, insulin resistance, and obesity | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| EP-1301516-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2003-04-16 | — | — | EP | disclosed |
| US-20020151561-A1 | Modulators of Protein Tyrosine Phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-10-17 | — | — | US | disclosed |
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-07-25 | — | — | US | disclosed |
| US-6410556-B1 | ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2002-06-25 | — | — | US | disclosed |
| EP-1214324-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | disclosed |
| EP-1214060-A2 | METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | disclosed |
| WO-2002004458-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001019830-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) | NOVO NORDISK A/S (DK) | 2001-03-22 | — | — | WO | disclosed |
| WO-2001017516-A2 | METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK A/S (DK) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151561-A1 | Modulators of Protein Tyrosine Phosphatases (PTPases) | PTPRO, PTPN1, PTPRS | OPRD1 2423/4885OPRK1 3851/4885OPRM1 3691/4885 |
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | PTPN1, PTPRO, PTPRS | OPRD1 2463/4885OPRK1 3824/4885OPRM1 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.